Construction of a predictive model based on the risk of relapse after cytarabine consolidation therapy in acute myeloid leukemia patients
The Oncologist · 09.03.2026 · 31 (4)
DOI: 10.1093/oncolo/oyag088 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 16.03.2026. Verfasst von Min Ji und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, People's Republic of China. Hauptthemen laut MEDLINE: Cytarabine, Leukemia, Myeloid, Acute, Antimetabolites, Antineoplastic, Neoplasm Recurrence, Local. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taishan Scholars Program, National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Background
Patients with acute myeloid leukemia (AML) are still at risk of relapse after consolidation therapy with cytarabine. Therefore, early identification and intervention of patients at high risk of relapse is crucial.
Methods
This single-center retrospective study analyzed the clinical data of 355 patients with AML (non-APL) who received cytarabine consolidation therapy. Key factors affecting relapse were identified by least absolute shrinkage and selection operator regression, and a predictive model for relapse after cytarabine consolidation therapy was constructed and internally validated.
Results
The study showed that age ≥50 years, female, DNMT3A mutation, TP53 mutation, IDH1 mutation, CBF-AML, white blood cell (WBC) ≥30 × 109/L, 2 courses of induction therapy, 1-2 courses of cytarabine consolidation therapy and cumulative dose of cytarabine <36 g were significantly correlated with relapse after cytarabine consolidation therapy in AML patients. Constructing a nomogram using the above factors and validating it with receiver operating characteristic, calibration curves showed that it has good discrimination and prediction. Patients were categorized into high-risk and low-risk groups based on the median risk score of the model, and there were significant differences in overall survival and event-free survival between the two groups.
Conclusion
Predictive models based on age, sex, DNMT3A, TP53, IDH1, CBF-AML, WBC count, induction therapy course, cytarabine consolidation course, and cumulative dose can effectively assess the relapse risk after receiving cytarabine consolidation therapy in AML patients and provide a reference for clinical decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, People's Republic of China.
- Shandong Key Laboratory of Hematological Diseases and Immune Microenvironment, Qilu Hospital, Shandong University, Jinan 250012, People's Republic of China.
- Interdisciplinary Center, Shandong University, Jinan 250100, People's Republic of China.
ORCID-Profile: Jingjing Ye
Förderung
- Taishan Scholars Program
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
Zitieren
APA
Ji, M., Hao, Y., Li, W., Zhou, Y., Jia, R., Li, W., Jin, S., Dai, M., Chang, M., Feng, L., Liu, T., Zhang, D., Ji, C., & Ye, J. (2026). Construction of a predictive model based on the risk of relapse after cytarabine consolidation therapy in acute myeloid leukemia patients. The Oncologist, 31(4). https://doi.org/10.1093/oncolo/oyag088
Vancouver
Ji M, Hao Y, Li W, Zhou Y, Jia R, Li W, et al. Construction of a predictive model based on the risk of relapse after cytarabine consolidation therapy in acute myeloid leukemia patients. The Oncologist. 2026;31(4). doi:10.1093/oncolo/oyag088
BibTeX
@article{Ji2026,
author = {Ji, Min and Hao, Yiping and Li, Wei and Zhou, Ying and Jia, Ruinan and Li, Wěi and Jin, Shumin and Dai, Min and Chang, Mengyuan and Feng, Lei and Liu, Tingting and Zhang, Di and Ji, Chunyan and Ye, Jingjing},
title = {Construction of a predictive model based on the risk of relapse after cytarabine consolidation therapy in acute myeloid leukemia patients},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {4},
doi = {10.1093/oncolo/oyag088}
}
EUVIMED